48 min
PIP008 UK Share Review of Bioventix and The Incredible Profitability of Diagnostic Antibodies Private Investor's Podcasts
-
- Investing
This time Maynard Paton and Roland Head discuss the investment potential of Bioventix (BVXP) and diagnostic antibodies.
Both Maynard and Roland hold AIM-listed Bioventix with Maynard's 2016 purchase of Bioventix at £11 and the shares now representing 12% of his portfolio. Roland later in 2021.
Maynard and Roland break down this incredibly profitable company which has operating margins of over 70% and has maintained those margins for over five years.
They discuss the recent AGM attended by Maynard, how Bioventix generates cash, future pipeline, the financials, dividends and current risks to the value and share price of this AIM-listed UK company, Bioventix.
Maynard's 2016 purchase of Bioventix at £11 and the shares now representing 12% of my portfolio. Roland buying Bioventix at £36 during 2021. What antibodies are, how they work within blood tests and Bioventix’s range of diagnostic antibodies. Bioventix’s financial track record and how antibody royalties support incredible margins. Bioventix’s laboratory, customers and industry competition. How successful diagnostic antibodies can earn royalties for more than 20 years. An example of a new diagnostic antibody dislodging an established diagnostic antibody. Bioventix’s lack of visibility on what hospitals pay for blood tests, the volumes of antibodies being used and what customers use antibodies for. Bioventix’s superb dividend record. AGM protest votes and boardroom diversity. Industrial pollution R&D, barbecued sausages and a low spreadsheet value. Alzheimer’s R&D and a new treatment for the disease. The academic publication covering antibody test results at the University of Gothenburg. The potential income from Alzheimer’s testing being a “2030s thing“. Bioventix’s investments, further Alzheimer’s research and future growth rates. The dependence on vitamin D testing and other shareholder risks. How the £40 shares appear on a dividend basis and possible future returns. Reasons to sell Bioventix and concluding thoughts. Hope you enjoy it and have a wonderful day.
Maynard & Roland.
If you like the episode, please subscribe for future company reviews.
Maynard & Roland Resources:
Follow Maynard on Twitter: https://twitter.com/maynardpaton
Follow Roland on Twitter: https://twitter.com/rolandhead
Visit Maynard’s Quality UK Investment website here https://maynardpaton.com/
Visit Roland’s Dividends Investing website here: https://www.rolandhead.com/
Visit Fund Your Retirement: https://www.fundyourretirement.com/
This time Maynard Paton and Roland Head discuss the investment potential of Bioventix (BVXP) and diagnostic antibodies.
Both Maynard and Roland hold AIM-listed Bioventix with Maynard's 2016 purchase of Bioventix at £11 and the shares now representing 12% of his portfolio. Roland later in 2021.
Maynard and Roland break down this incredibly profitable company which has operating margins of over 70% and has maintained those margins for over five years.
They discuss the recent AGM attended by Maynard, how Bioventix generates cash, future pipeline, the financials, dividends and current risks to the value and share price of this AIM-listed UK company, Bioventix.
Maynard's 2016 purchase of Bioventix at £11 and the shares now representing 12% of my portfolio. Roland buying Bioventix at £36 during 2021. What antibodies are, how they work within blood tests and Bioventix’s range of diagnostic antibodies. Bioventix’s financial track record and how antibody royalties support incredible margins. Bioventix’s laboratory, customers and industry competition. How successful diagnostic antibodies can earn royalties for more than 20 years. An example of a new diagnostic antibody dislodging an established diagnostic antibody. Bioventix’s lack of visibility on what hospitals pay for blood tests, the volumes of antibodies being used and what customers use antibodies for. Bioventix’s superb dividend record. AGM protest votes and boardroom diversity. Industrial pollution R&D, barbecued sausages and a low spreadsheet value. Alzheimer’s R&D and a new treatment for the disease. The academic publication covering antibody test results at the University of Gothenburg. The potential income from Alzheimer’s testing being a “2030s thing“. Bioventix’s investments, further Alzheimer’s research and future growth rates. The dependence on vitamin D testing and other shareholder risks. How the £40 shares appear on a dividend basis and possible future returns. Reasons to sell Bioventix and concluding thoughts. Hope you enjoy it and have a wonderful day.
Maynard & Roland.
If you like the episode, please subscribe for future company reviews.
Maynard & Roland Resources:
Follow Maynard on Twitter: https://twitter.com/maynardpaton
Follow Roland on Twitter: https://twitter.com/rolandhead
Visit Maynard’s Quality UK Investment website here https://maynardpaton.com/
Visit Roland’s Dividends Investing website here: https://www.rolandhead.com/
Visit Fund Your Retirement: https://www.fundyourretirement.com/
48 min